MAPT and Cognitive impairment: We included 289 participants from the TRIAD cohort (n = 174 cognitively unimpaired, n = 74 with mild cognitive impairment (MCI), n = 41 with Alzheimer's disease (AD)) who were separated according to brain Aβ status and tau accumulation in different Braak stages by [18F]AZD4694 PET and [18F]MK6240 PET respectively.